Cargando…

Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives

For over 30 years, our TE has processed, controlled for quality and distributed cryopreserved allograft valves for human application. We present a review of this activity and future perspectives of cardiovascular tissue banking. The donor age and medical/behavioral history are in compliance with the...

Descripción completa

Detalles Bibliográficos
Autor principal: Jashari, Ramadan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853167/
https://www.ncbi.nlm.nih.gov/pubmed/33532987
http://dx.doi.org/10.1007/s10561-021-09902-2
_version_ 1783645916018769920
author Jashari, Ramadan
author_facet Jashari, Ramadan
author_sort Jashari, Ramadan
collection PubMed
description For over 30 years, our TE has processed, controlled for quality and distributed cryopreserved allograft valves for human application. We present a review of this activity and future perspectives of cardiovascular tissue banking. The donor age and medical/behavioral history are in compliance with the regulations of the EUMS. Allograft morphology and function are evaluated in a class A cleanroom. Tests for viral/bacterial infection, histological control of structure/infection/malignancy and control-rate cryopreservation are performed. A total of 7562 hearts were sent to our TE, whereas 7290 valves (pulmonary, aortic and mitral) were transplanted. The donations increased over time: 1934, 2566 and 3062 hearts were donated during the first, second and third decades (increases of 32.7 and 19.3% during the second and third decades). Likewise, there was a significant increase in transplantations with 2050, 2550 and 2690 valves implanted during the first, second and third decades (24.4 and 5.5% increase during the second and third decades). A total of 4475 pulmonary (61.4%), 2760 aortic (37.9%) and 55 mitral valves (0.7%) were transplanted. Outstanding long-term results in adults and evidence of immune-related deterioration of allografts in neonates and infants were demonstrated. Decellularization was suggested as a solution. One hundred pulmonary and 180 aortic valves were sent for transplantation after decellularization for the ESPOIR and ARISE clinical trials and beyond. The donation and transplantation activity increased progressively. Although cryopreserved valves represent the best substitute for diseased valves, accelerated failure appears after implantation in neonates and infants. The implementation of new technologies, such as decellularization, as a standard procedure for treatment of allograft valves will offer further improvements in allograft quality and increase of durability.
format Online
Article
Text
id pubmed-7853167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-78531672021-02-03 Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives Jashari, Ramadan Cell Tissue Bank Article For over 30 years, our TE has processed, controlled for quality and distributed cryopreserved allograft valves for human application. We present a review of this activity and future perspectives of cardiovascular tissue banking. The donor age and medical/behavioral history are in compliance with the regulations of the EUMS. Allograft morphology and function are evaluated in a class A cleanroom. Tests for viral/bacterial infection, histological control of structure/infection/malignancy and control-rate cryopreservation are performed. A total of 7562 hearts were sent to our TE, whereas 7290 valves (pulmonary, aortic and mitral) were transplanted. The donations increased over time: 1934, 2566 and 3062 hearts were donated during the first, second and third decades (increases of 32.7 and 19.3% during the second and third decades). Likewise, there was a significant increase in transplantations with 2050, 2550 and 2690 valves implanted during the first, second and third decades (24.4 and 5.5% increase during the second and third decades). A total of 4475 pulmonary (61.4%), 2760 aortic (37.9%) and 55 mitral valves (0.7%) were transplanted. Outstanding long-term results in adults and evidence of immune-related deterioration of allografts in neonates and infants were demonstrated. Decellularization was suggested as a solution. One hundred pulmonary and 180 aortic valves were sent for transplantation after decellularization for the ESPOIR and ARISE clinical trials and beyond. The donation and transplantation activity increased progressively. Although cryopreserved valves represent the best substitute for diseased valves, accelerated failure appears after implantation in neonates and infants. The implementation of new technologies, such as decellularization, as a standard procedure for treatment of allograft valves will offer further improvements in allograft quality and increase of durability. Springer Netherlands 2021-02-02 2021 /pmc/articles/PMC7853167/ /pubmed/33532987 http://dx.doi.org/10.1007/s10561-021-09902-2 Text en © The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Jashari, Ramadan
Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title_full Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title_fullStr Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title_full_unstemmed Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title_short Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives
title_sort transplantation of cryopreserved human heart valves in europe: 30 years of banking in brussels and future perspectives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853167/
https://www.ncbi.nlm.nih.gov/pubmed/33532987
http://dx.doi.org/10.1007/s10561-021-09902-2
work_keys_str_mv AT jashariramadan transplantationofcryopreservedhumanheartvalvesineurope30yearsofbankinginbrusselsandfutureperspectives